Literature DB >> 32074140

Microvasculopathy and soft tissue calcification in mice are governed by fetuin-A, magnesium and pyrophosphate.

Anne Babler1, Carlo Schmitz1, Andrea Buescher1, Marietta Herrmann1,2, Felix Gremse3, Theo Gorgels4, Juergen Floege5, Willi Jahnen-Dechent1.   

Abstract

Calcifications can disrupt organ function in the cardiovascular system and the kidney, and are particularly common in patients with chronic kidney disease (CKD). Fetuin-A deficient mice maintained against the genetic background DBA/2 exhibit particularly severe soft tissue calcifications, while fetuin-A deficient C57BL/6 mice remain healthy. We employed molecular genetic analysis to identify risk factors of calcification in fetuin-A deficient mice. We sought to identify pharmaceutical therapeutic targets that could be influenced by dietary of parenteral supplementation. We studied the progeny of an intercross of fetuin-A deficient DBA/2 and C57BL/6 mice to identify candidate risk genes involved in calcification. We determined that a hypomorphic mutation of the Abcc6 gene, a liver ATP transporter supplying systemic pyrophosphate, and failure to regulate the Trpm6 magnesium transporter in kidney were associated with severity of calcification. Calcification prone fetuin-A deficient mice were alternatively treated with parenteral administration of fetuin-A dietary magnesium supplementation, phosphate restriction, or by or parenteral pyrophosphate. All treatments markedly reduced soft tissue calcification, demonstrated by computed tomography, histology and tissue calcium measurement. We show that pathological ectopic calcification in fetuin-A deficient DBA/2 mice is caused by a compound deficiency of three major extracellular and systemic inhibitors of calcification, namely fetuin-A, magnesium, and pyrophosphate. All three of these are individually known to contribute to stabilize protein-mineral complexes and thus inhibit mineral precipitation from extracellular fluid. We show for the first time a compound triple deficiency that can be treated by simple dietary or parenteral supplementation. This is of special importance in patients with advanced CKD, who commonly exhibit reduced serum fetuin-A, magnesium and pyrophosphate levels.

Entities:  

Year:  2020        PMID: 32074140     DOI: 10.1371/journal.pone.0228938

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  8 in total

Review 1.  Tissue chaperoning-the expanded functions of fetuin-A beyond inhibition of systemic calcification.

Authors:  Stefan Rudloff; Willi Jahnen-Dechent; Uyen Huynh-Do
Journal:  Pflugers Arch       Date:  2022-04-11       Impact factor: 4.458

2.  Level of Serum Fetuin-A Correlates with Heart Rate in Obstructive Sleep Apnea Patients without Metabolic and Cardiovascular Comorbidities.

Authors:  Elżbieta Reichert; Jerzy Mosiewicz; Wojciech Myśliński; Andrzej Jaroszyński; Agata Stanek; Klaudia Brożyna-Tkaczyk; Barbara Madejska-Mosiewicz
Journal:  Int J Environ Res Public Health       Date:  2022-05-25       Impact factor: 4.614

Review 3.  Multiple Pathways for Pathological Calcification in the Human Body.

Authors:  Netta Vidavsky; Jennie A M R Kunitake; Lara A Estroff
Journal:  Adv Healthc Mater       Date:  2020-12-04       Impact factor: 9.933

Review 4.  Biomolecules Orchestrating Cardiovascular Calcification.

Authors:  Yin Tintut; Henry M Honda; Linda L Demer
Journal:  Biomolecules       Date:  2021-10-07

5.  Sclerostin Protects Against Vascular Calcification Development in Mice.

Authors:  Annelies De Maré; Britt Opdebeeck; Ellen Neven; Patrick C D'Haese; Anja Verhulst
Journal:  J Bone Miner Res       Date:  2022-02-15       Impact factor: 6.390

6.  Post-translational modifications glycosylation and phosphorylation of the major hepatic plasma protein fetuin-A are associated with CNS inflammation in children.

Authors:  Frederik Ricken; Ahu Damla Can; Steffen Gräber; Martin Häusler; Willi Jahnen-Dechent
Journal:  PLoS One       Date:  2022-10-07       Impact factor: 3.752

7.  Calciprotein Particles: Balancing Mineral Homeostasis and Vascular Pathology.

Authors:  Anton G Kutikhin; Lian Feenstra; Alexander E Kostyunin; Arseniy E Yuzhalin; Jan-Luuk Hillebrands; Guido Krenning
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-03-11       Impact factor: 8.311

8.  Risk factors and implications associated with renal mineralization in chronic kidney disease in cats.

Authors:  Pak-Kan Tang; Rosanne E Jepson; Yu-Mei Chang; Rebecca F Geddes; Mark Hopkinson; Jonathan Elliott
Journal:  J Vet Intern Med       Date:  2022-01-19       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.